Join to View Full Profile
160 E 34th St# NyuNew York, NY 10016
Phone+1 212-731-5795
Fax+1 212-731-5342
Dr. Adams is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
NYU Grossman Long Island School of MedicineResidency, Internal Medicine, 1997 - 2000
Friedrich-Schiller-Universität JenaClass of 1995
Certifications & Licensure
NY State Medical License 2000 - 2026
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine Start of enrollment: 2005 Jul 01
- NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) Start of enrollment: 2005 Aug 24
- NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors Start of enrollment: 2006 Mar 21
- Join now to see all
Publications & Presentations
PubMed
- Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer.Sylvia Adams, Sandra Demaria, Darawan Rinchai, Ena Wang, Yelena Novik
Journal for Immunotherapy of Cancer. 2025-04-05 - 1 citationsSubcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (...Adrienne G Waks, Emily L Chen, Noah Graham, Anna Mae Frey, Kenneth Almeida
JCO Oncology Practice. 2025-03-01 - 3 citationsAcademic Uphill Battle to Personalize Treatment for Patients With Stage II/III Triple-Negative Breast Cancer.Marleen Kok, Robbert-Jan Gielen, Sylvia Adams, Jochen K Lennerz, Priyanka Sharma
Journal of Clinical Oncology. 2024-10-20
Journal Articles
- Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 StudyM C Liu, R Nanda, H S Rugo, E P Winer, S Adams, Annals of Oncology
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast CancerAmreen Husain, Sylvia Adams, Hope S Rugo, Carlos H Barrios, Eric P Winer, The New England Journal of Medicine
Press Mentions
SABCS Highlights in Triple-negative Breast CancerDecember 9th, 2022- Researchers: Breast Cancer Drug Could Help More PatientsJune 6th, 2022
- Breast Cancer Drug Shows Promise, Opens New Treatment Possibilities to Thousands of PatientsJune 6th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
